PRESS RELEASE | Basel, Switzerland, December 5, 2023
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases.